Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KANAMYCIN SULFATE vs AKTOB
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing m RNA misreading.
Immunosuppressant; inhibits T-cell activation by binding to cyclophilin and inhibiting calcineurin, thereby blocking IL-2 transcription.
Short-term treatment of serious infections caused by susceptible strains of bacteria (e.g., Escherichia coli, Proteus species, Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, Acinetobacter species),Adjunctive therapy in staphylococcal infections,Mycobacterium tuberculosis infections (as second-line agent)
Prevention of organ rejection in kidney, liver, and heart transplants,Rheumatoid arthritis,Psoriasis
15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.
Adults: 10 mg orally once daily.
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 30-60 hours in severe renal impairment (Cr Cl <10 m L/min).
Terminal elimination half-life is 8-12 hours; prolonged in renal impairment (up to 20-30 hours in anuria).
Not metabolized; excreted unchanged by glomerular filtration.
Hepatic via CYP3A4 enzyme system; major metabolites include AM1, AM9, and AM4N.
Renal excretion of unchanged drug accounts for 80-90% of elimination; minor biliary excretion (<1%) and fecal elimination (<1%).
Renal: 70-80% unchanged; biliary/fecal: 10-15% as metabolites.
Low; approximately 0-10%, primarily to albumin.
20-30% primarily to albumin.
0.2-0.4 L/kg; reflects distribution primarily into extracellular fluid.
0.25-0.4 L/kg; indicates distribution primarily in extracellular fluid.
Intramuscular: ~100%; Oral: <1% (not absorbed); Ophthalmic: minimal systemic absorption (<1%).
Intramuscular: approximately 90%; oral: not absorbed (0% due to degradation in GI tract).
GFR 50-90 m L/min: administer every 24 hours. GFR 10-50 m L/min: administer every 24-72 hours. GFR <10 m L/min: administer every 72-96 hours. Dose adjustments based on serum concentrations.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 5 mg once daily; GFR <15 m L/min or dialysis: 2.5 mg once daily.
No dose adjustment required for hepatic impairment. Kanamycin is primarily renally eliminated.
Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended.
Neonates: 7.5-10 mg/kg IV every 12 hours. Infants and children: 15 mg/kg/day IM or IV divided every 8-12 hours. Maximum total daily dose: 1.5 g.
Not established for children <18 years.
Lower initial and maintenance doses due to age-related decrease in renal function. Monitor renal function and serum concentrations closely. Consider dosing based on ideal body weight and renal function.
No specific dose adjustment; monitor for hypotension and renal function.
Boxed warnings: Neurotoxicity (ototoxicity vestibular and auditory), nephrotoxicity, and neuromuscular blockade. Risk increases with high doses, prolonged use, renal impairment, and concurrent use of other ototoxic/nephrotoxic drugs. Monitor renal function and drug levels. Avoid in pregnancy.
Increased risk of lymphomas and other malignancies, particularly of the skin. Increased susceptibility to infections. Cyclosporine can cause nephrotoxicity and hepatotoxicity.
Ototoxicity (vestibular and auditory) can be irreversible, especially with renal impairment, high doses, prolonged therapy, or concurrent ototoxic drugs. Nephrotoxicity risk; monitor renal function and serum drug levels. Neuromuscular blockade risk, especially with anesthetics, neuromuscular blocking agents, or in patients with neuromuscular disorders. Superinfection, Clostridium difficile diarrhea. Use caution in elderly, dehydration, and pre-existing renal impairment.
Nephrotoxicity, hepatotoxicity, hypertension, hyperkalemia, neurotoxicity, increased risk of infections and malignancies, anaphylaxis (IV formulation).
Hypersensitivity to kanamycin or other aminoglycosides; myasthenia gravis (increased risk of neuromuscular blockade).
Hypersensitivity to cyclosporine or any component of the formulation, abnormal renal function, uncontrolled hypertension, malignancies, concurrent use with PUVA or UVB therapy in psoriasis.
No significant food interactions known. Kanamycin absorption is not affected by food. However, maintain adequate hydration.
No significant food interactions. Avoid alcohol while taking this medication.
First trimester: No evidence of teratogenicity in humans, but crosses placenta and may cause fetal ototoxicity. Second and third trimesters: Risk of fetal ototoxicity (irreversible bilateral hearing loss) and nephrotoxicity, especially with prolonged or high-dose therapy.
First trimester: Limited human data; animal studies show adverse effects at high doses. Avoid unless benefit outweighs risk. Second/third trimester: No documented teratogenicity; monitor for fetal growth restriction and oligohydramnios.
Excreted into breast milk in small amounts; M/P ratio not established. Use caution in breastfeeding due to potential for infant ototoxicity and nephrotoxicity; monitor infant for diarrhea, rash, and hearing loss.
Not recommended during breastfeeding. M/P ratio unknown; potential infant exposure via milk.
No standard dosing adjustment required for pregnancy; however, increased volume of distribution may require higher loading doses. Tight therapeutic drug monitoring indicated due to altered renal clearance.
No standard dose adjustment; increased clearance in pregnancy may require higher doses; therapeutic drug monitoring advised.
Kanamycin is an aminoglycoside antibiotic used primarily for serious Gram-negative infections. Monitor peak and trough levels to avoid ototoxicity and nephrotoxicity; typical therapeutic peaks: 15-30 mcg/m L, troughs <5 mcg/m L. Avoid concurrent use with other nephrotoxic or ototoxic drugs (e.g., furosemide, vancomycin, cisplatin). Adjust dose in renal impairment using creatinine clearance. Intramuscular administration preferred; avoid rapid IV push. Use with caution in myasthenia gravis or Parkinson's disease due to neuromuscular blockade potential.
AKTOB is a beta-lactam antibiotic; monitor for hypersensitivity reactions, especially in patients with penicillin allergy. Adjust dose in renal impairment (Cr Cl <30 m L/min). Administer by slow IV infusion over 3-5 minutes or as directed. Observe for signs of Clostridioides difficile infection.
Complete the entire course of therapy even if you feel better.,Report any hearing loss, tinnitus, dizziness, or changes in urination immediately.,Stay well hydrated unless instructed otherwise.,Avoid taking other medications without consulting your doctor, especially diuretics or other antibiotics.,This medication may cause nausea; take with food if tolerated.
Complete the full course of therapy even if symptoms improve.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing immediately.,Inform your doctor if you have kidney problems or are on dialysis.,This medication may cause diarrhea; do not treat with anti-diarrheal medications without consulting your doctor.,Store at room temperature away from moisture and heat.
"Kanamycin, an aminoglycoside antibiotic, may reduce the renal clearance of Lornoxicam, a nonsteroidal anti-inflammatory drug (NSAID), by competitively inhibiting tubular secretion or altering renal perfusion. This interaction can lead to elevated serum levels of Lornoxicam, increasing the risk of dose-dependent adverse effects such as gastrointestinal bleeding, renal impairment, and central nervous system toxicity. Clinically, patients may present with worsening renal function or NSAID-related side effects, especially in those with pre-existing renal compromise or dehydration."
"Kanamycin, an aminoglycoside antibiotic, increases the nephrotoxic potential of Cisplatin, a platinum-based chemotherapeutic agent, through additive damage to the proximal renal tubules. This synergistic effect elevates the risk of acute kidney injury, particularly in patients with pre-existing renal impairment or those receiving other nephrotoxic drugs. Clinically, this interaction may lead to reduced renal function, electrolyte imbalances, and delayed elimination of both agents, potentially exacerbating systemic toxicity."
"The coadministration of Kanamycin and Vancomycin results in synergistic nephrotoxicity due to additive insult to the proximal renal tubules. Both aminoglycoside and glycopeptide antibiotics accumulate in the renal cortex, causing tubular cell necrosis and acute kidney injury (AKI). This interaction significantly increases the risk of renal impairment, potentially leading to irreversible kidney damage, particularly in patients with pre-existing renal compromise, advanced age, or prolonged therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KANAMYCIN SULFATE vs AKTOB, answered by our medical review team.
KANAMYCIN SULFATE is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing m RNA misreading.. AKTOB is a Aminoglycoside Antibiotic (Ophthalmic) that works by Immunosuppressant; inhibits T-cell activation by binding to cyclophilin and inhibiting calcineurin, thereby blocking IL-2 transcription.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KANAMYCIN SULFATE and AKTOB depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KANAMYCIN SULFATE is: 15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.. The standard adult dose of AKTOB is: Adults: 10 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KANAMYCIN SULFATE and AKTOB in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KANAMYCIN SULFATE is classified as Category C. First trimester: No evidence of teratogenicity in humans, but crosses placenta and may cause fetal ototoxicity. Second and third trimesters: Risk of fetal ototoxicity (irreversible. AKTOB is classified as Category C. First trimester: Limited human data; animal studies show adverse effects at high doses. Avoid unless benefit outweighs risk. Second/third trimester: No documented teratogenicity; m. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.